Eligibility, any sex, with Healing Surgical Wounds or Pain Measurement. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Self-Reported Patient Discomfort as Assessed by a Visual Analogue ScalePrimary· One week
At the end of their surgical appointment, patients will be given a Visual Analogue Scale (VAS) questionnaire to rate their post-operative pain by making a mark along a 10-cm line (0 = no pain, 10 = unbearable pain) for each night of the first post-operative week. At the one-week post-operative appointment, the participants will return their VAS questionnaires and their reported post-operative discomfort for each night of the initial post-operative week will be tabulated.
Day 1
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
4.90
0.2 – 9.0
Control
2.45
0.0 – 9.3
Day 2
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
3.30
0.1 – 8.0
Control
0.83
0.0 – 4.3
Day 3
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
2.93
0.1 – 8.0
Control
0.72
0.0 – 3.5
Day 4
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
2.75
0.2 – 7.0
Control
0.40
0.0 – 1.5
Day 5
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
2.65
0.2 – 7.0
Control
0.32
0.0 – 1.2
Day 6
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
2.65
0.2 – 6.0
Control
0.16
0.0 – 0.5
Patient Discomfort as Assessed by Analgesic ConsumptionPrimary· One week
At the end of their surgical appointment, patients will be provided with a bag of 30 200-mg Ibuprofen tablets. At the one-week post-operative appointment, the participants will return any remaining Ibuprofen tablets and their total analgesic consumption for the initial post-operative week will be tabulated.
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
10.5
1.0 – 23.0
Control
6.0
0.0 – 16.0
Self-Reported Patient Discomfort as Assessed by a Oral Impacts on Daily Performance QuestionnairePrimary· One Week
At the one-week post-operative appointment, patients will complete a modified Oral Impacts on Daily Performance (OIDP) questionnaire to assess the effect of the palatal wound on their oral-health related quality of life during the first post-operative week. They will rate the overall frequency of disruptions that the palatal surgical site had on eating, speaking, oral hygiene, light physical work, participation in regular outings, sleeping, relaxing, smiling and laughing, their mood, and interpersonal interactions by making a mark along a 10-cm line (0 = never, 10 = constantly) for first post-
Frequency of Disruptions to Eating Food
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
7.52
3.0 – 9.6
Control
3.65
0.0 – 9.5
Severity of Disruptions to Eating Food
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
5.25
0.1 – 8.2
Control
2.65
0.1 – 5.3
Frequency of Disruptions to Speaking
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
4.73
0.9 – 7.3
Control
1.87
0.0 – 9.2
Severity of Disruptions to Speaking
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
3.28
0.1 – 7.4
Control
0.55
0.0 – 1.5
Frequency of Disruptions when Performing Oral Hygiene
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
5.18
1.0 – 9.1
Control
4.22
0.0 – 9.7
Severity of Disruptions when Performing Oral Hygiene
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
4.40
0.1 – 8.8
Control
4.98
0.2 – 9.7
Frequency of Disruptions when Performing Light Work
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
1.30
0.6 – 2.0
Control
0.25
0.0 – 1.0
Severity of Disruptions when Performing Light Work
Group
Value
95% CI
J. Morita AdvErl Evo Er:YAG Laser
0.90
0.1 – 1.9
Control
0.35
0.0 – 1.0
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected for the 6-week period during which the study was conducted for each patient..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to assess the effects of photobiomodulation (PBM) with an Er:YAG laser on the palatal donor site following subepithelial connective tissue graft (SECTG) surgery. Patient-centred outcomes and wound healing will be compared between a control group, who receives no laser treatment, and the test group receiving PBM therapy. It is hypothesized that laser stimulation will have a beneficial effect on the patient's post-operative experience as well as the healing of the tissues.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other recruiting trials for Healing Surgical Wounds
Currently open trials in the same condition.
NCT06261268 — Strip Graft w/ Xenogeneic Matrix vs Free Gingival Graft for the Augmentation of Peri-implant Keratinized Mucosa
· NA
· recruiting
Other University of Manitoba trials
Trials by the same sponsor.
NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
· Phase 2
· not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients
· NA
· not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes
· NA
· enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias
· NA
· recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 10 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03741062.